0000905148-23-001682.txt : 20231220
0000905148-23-001682.hdr.sgml : 20231220
20231220191700
ACCESSION NUMBER: 0000905148-23-001682
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231220
FILED AS OF DATE: 20231220
DATE AS OF CHANGE: 20231220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Walker Karin L
CENTRAL INDEX KEY: 0001559422
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35676
FILM NUMBER: 231502520
MAIL ADDRESS:
STREET 1: C/O PROTHENA CORPORATION PLC
STREET 2: 650 GATEWAY BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROTHENA CORP PUBLIC LTD CO
CENTRAL INDEX KEY: 0001559053
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C
STREET 2: GRAND CANAL DOCKLANDS
CITY: DUBLIN 2
STATE: L2
ZIP: D02 VK60
BUSINESS PHONE: 011-353-1-236-2500
MAIL ADDRESS:
STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C
STREET 2: GRAND CANAL DOCKLANDS
CITY: DUBLIN 2
STATE: L2
ZIP: D02 VK60
FORMER COMPANY:
FORMER CONFORMED NAME: Prothena Corp plc
DATE OF NAME CHANGE: 20121102
FORMER COMPANY:
FORMER CONFORMED NAME: Neotope Corp Ltd
DATE OF NAME CHANGE: 20120926
4
1
form4.xml
X0508
4
2023-12-20
0001559053
PROTHENA CORP PUBLIC LTD CO
PRTA
0001559422
Walker Karin L
C/O PROTHENA BIOSCIENCES INC
1800 SIERRA POINT PARKWAY
BRISBANE
CA
94005
true
Chief Accounting Officer
true
Ordinary Shares, par value $0.01 per share
2023-12-20
4
M
0
5000
13.53
A
5000
D
Ordinary Shares, par value $0.01 per share
2023-12-20
4
S
0
1678
36.6765
D
3322
D
Ordinary Shares, par value $0.01 per share
2023-12-20
4
S
0
3322
37.4499
D
0
D
Stock Option (Right to Buy)
13.53
2023-12-20
4
M
0
5000
0
D
2029-02-27
Ordinary Shares
5000
20000
D
The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023.
The transaction was executed in multiple trades in prices ranging from $36.095 to $37.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 3 of this Form 4.
The transaction was executed in multiple trades in prices ranging from $37.14 to $37.82, inclusive.
The shares subject to the option vested and became exercisable as to 25% of the total number of shares subject to the option on February 27, 2020, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
/s/ Michael J. Malecek, as Attorney-in-Fact for Karin L. Walker
2023-12-20